ArticleJournal of molecular histology2025
Liraglutide and denatonium benzoate attenuate T2DM-induced metabolic, neurological, and testicular changes in rats: Targeting oxidative stress, inflammation, and BCRP transporter.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats.Molecular metabolism · 2026Article
- CanInternational journal of molecular sciences · 2026Article
- The possible renoprotective effect of denatonium benzoate in a rat model of type 2 diabetes: role of Krüppel-like factor 6 (KLF6).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Diabetic testicular dysfunction and spermatogenesis impairment: mechanisms and therapeutic prospects.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) adversely affects various organs, including the brain and its blood barrier. In addition to the brain, hyperglycemia damages the testes. The testes possess blood-tissue barriers that share common characteristics and proteins with the blood-brain barrier (BBB), including breast cancer-resistant protein (BCRP). This study aimed to investigate the impact of uncontrolled DM on the brain and testes, with a specific focus on BCRP. Moreover, it examined the effects of liraglutide (Lira) and denatonium benzoate (DB), a bitter taste receptor agonist, on T2DM. Forty adult male rats were randomized into five groups: normal control, diabetic, diabetic + DB, diabetic + Lira, and diabetic + DB + Lira. T2DM was induced using fructose and streptozotocin (STZ). After eight weeks of treatment, rats were sacrificed, and samples of blood, semen, testes, and brain were collected to evaluate metabolic and semen parameters, oxidative stress, inflammatory markers, histological features of the brain and testes, and BCRP expression. DB and Lira, both individually and in combination, mitigated fructose/STZ-induced hyperglycemia and dyslipidemia. Additionally, they enhanced SOD activity and reduced MDA, TNFα, and IL-6 levels in the brain and testes, alongside improving sperm quality and serum levels of FSH, LH, and testosterone. Rats treated with DB, Lira, or DB + Lira demonstrated improved brain and testicular tissue architecture. BCRP expression was upregulated in the brains and testes of Lira- and DB + Lira-treated rats. These findings indicated that DB positively affects the metabolic profile of T2DM. Furthermore, Lira and DB provided protection against T2DM-induced brain and testicular damage.
Indexed as
Identifiers
39881033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.